You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

murine monoclonal antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroblastoma Trial in New York (anti-GD2 murine IgG3 mAb 3F8)

Completed
Has Results
  • Neuroblastoma
  • anti-GD2 murine IgG3 monoclonal antibody 3F8
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Apr 21, 2022

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Antibody-mediated Rejection, Kidney Tranplant Trial in Hangzhou (Daratumumab)

Not yet recruiting
  • Antibody-mediated Rejection
  • Kidney Tranplant
  • Hangzhou, Zhejiang, China
    79# Qingchun Road
Jun 21, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

Acquired Hemophilia Trial in Tianjin (Daratumumab)

Recruiting
  • Acquired Hemophilia
  • Tianjin, China
    Chinese Academy of Medical Science and Blood Disease Hospital
May 5, 2023

Atopic Dermatitis Trial in Shanghai (MG-K10/Placebo)

Active, not recruiting
  • Atopic Dermatitis
  • MG-K10/Placebo
  • Shanghai, China
    Huashan Hospital Affiliated to Fudan University
Aug 31, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

Not yet recruiting
  • MSS
  • Rectal Cancer
  • Sintilimab with Interleukin-2
  • (no location specified)
Nov 1, 2023

Diabetic Polyneuropathy Trial in Rochester, Aarhus, Copenhagen (Eptinezumab, Placebo)

Not yet recruiting
  • Diabetic Polyneuropathy
  • Rochester, Minnesota
  • +2 more
Jun 30, 2023

Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)

Completed
Has Results
  • Ovarian Cancer
  • 90Y-hu3S193
  • 111In-hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer Trial in Palo Alto (Utomilumab, Trastuzumab,

Completed
Has Results
  • HER2 Positive Breast Carcinoma
  • +6 more
  • Palo Alto, California
    Stanford University, School of Medicine
Sep 22, 2022

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)

Recruiting
  • Safety and Efficacy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Sep 27, 2023

Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)

Terminated
Has Results
  • Ovarian Cancer
  • Monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma Trial in Changchun (Rituximab,

Recruiting
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic T-cell Lymphoma
  • Changchun, Jilin, China
    The First Bethune Hospital of Jilin University
Apr 7, 2023

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell Trial in Najing (Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Lymphoma, T-Cell
  • Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
  • Najing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Sep 26, 2022

COVID-19 Trial in Joondalup (VYD222, Placebo)

Recruiting
  • COVID-19
  • Joondalup, Western Australia, Australia
    Linear Clinical Research
Apr 3, 2023

Acute Gout Trial in Wuhan, Linyi, Shanghai (Recombinant Anti-IL-1ß Humanized Monoclonal Antibody Injection 100 mg (phase Ib),

Recruiting
  • Acute Gout
  • Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib)
  • +6 more
  • Wuhan, Hubei, China
  • +2 more
Oct 17, 2022

Lymphoma Trial (BYON4228 + Rituximab)

Not yet recruiting
  • Lymphoma
  • BYON4228 + Rituximab
  • (no location specified)
Feb 20, 2023

Pyoderma, Pyoderma Gangrenosum, Pyoderma Vegetans Trial in Minsk, Riga (Monoclonal antibody (Mab) sB24M)

Active, not recruiting
  • Pyoderma
  • +3 more
  • Monoclonal antibody (Mab) sB24M
  • Minsk, Belarus
  • +1 more
Jul 8, 2022

Assess New Participant's Perspectives Beyond Clinical Efficacy

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
    • (no location specified)
    Nov 7, 2023

    Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

    Not yet recruiting
    • Colorectal Cancer
    • Hangzhou, Zhejiang, China
      Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
    Jan 30, 2023

    Colorectal Cancer Trial in New York (mAb hu3S193)

    Terminated
    Has Results
    • Colorectal Cancer
    • monoclonal antibody hu3S193
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    Psoriasis Trial in Shanghai, Kunming (Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection, Placebo)

    Active, not recruiting
    • Psoriasis
    • Recombinant Anti-IL-17A Humanized Monoclonal Antibody Injection
    • Placebo
    • Shanghai, Shanghai, China
    • +2 more
    Nov 7, 2022